| 1.22 -0.07 (-5.43%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.79 | 1-year : | 2.05 |
| Resists | First : | 1.53 | Second : | 1.75 |
| Pivot price | 1.36 |
|||
| Supports | First : | 1.17 | Second : | 0.98 |
| MAs | MA(5) : | 1.27 |
MA(20) : | 1.36 |
| MA(100) : | 2.1 |
MA(250) : | 2.2  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 12.1 |
D(3) : | 18.2 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 5.48 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABVC ] has closed above bottom band by 7.4%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.18 - 1.18 | 1.18 - 1.19 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Tue, 03 Mar 2026
Restatement and asset surge reshape ABVC BioPharma (NASDAQ: ABVC) - Stock Titan
Tue, 03 Mar 2026
ABVC BioPharma - quarterly period ended September, 2025 financial statements should not be relied upon - marketscreener.com
Tue, 03 Mar 2026
ABVC BioPharma Reports 2025 Form 10-K - Yahoo Finance
Mon, 02 Mar 2026
ABVC BioPharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Tue, 24 Feb 2026
ABVC BioPharma Provides Corporate and Structural Update - Yahoo Finance
Mon, 03 Nov 2025
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 3.3 (%) |
| Shares Short | 248 (K) |
| Shares Short P.Month | 343 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.5 |
| Profit Margin | 0 % |
| Operating Margin | -146.6 % |
| Return on Assets (ttm) | -17.3 % |
| Return on Equity (ttm) | -47.8 % |
| Qtrly Rev. Growth | 104.5 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -4.36 |
| PEG Ratio | 0 |
| Price to Book value | 2.39 |
| Price to Sales | 37.15 |
| Price to Cash Flow | -13.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|